Sertindole

Sertindole (Lu 23-174) is an orally active 5-HT2A, 5-HT2C, dopamine D2, and αl-adrenergic receptors antagonist. Sertindole shows antipsychotic activity and anti-proliferative activity to multiple cancer cells[1][2][3].

Product Specifications

CAS Number

[106516-24-9]

Product Name Alternative

Lu 23-174

UNSPSC

12352005

Hazard Statement

H315, H319, H335, H413

Target

5-HT Receptor; Adrenergic Receptor; Autophagy; Dopamine Receptor

Type

Reference compound

Related Pathways

Autophagy; GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Sertindole.html

Purity

99.92

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

FC1=CC=C(N2C3=CC=C(Cl)C=C3C(C4CCN(CCN5CCNC5=O)CC4)=C2)C=C1

Molecular Formula

C24H26ClFN4O

Molecular Weight

440.94

Precautions

H315, H319, H335, H413

References & Citations

[1]David Murdoch, et al. Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;20 (3) :233-55.|[2]Wei Zhang, et al. Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep. 2018 Oct 25;8 (1) :15753.|[3]Mario F Juruena, et al. Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis. 2011 May 17;3:75-85.